Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.

导出 LinkOut

翻译打印收藏纠错

作者： Barbora,Weinbergerová ^[1] ; Jiří,Mayer ^[1] ; Tomáš,Kabut ^[1] ; Wolfgang R,Sperr ^[2] ; Jana,Števková ^[3] ; Anna,Jonášová ^[4] ; Martin,Čerňan ^[5] ; Susanne,Herndlhofer ^[6] ; Iveta,Oravcová ^[7] ; Jiří,Šrámek ^[8] ; Jan,Novák ^[9] ; Radka,Štěpánová ^[10] ; Tomáš,Szotkowski ^[5] ; Luboš,Drgoňa ^[7] ; Pavel,Žák ^[3] ; Peter,Valent ^[2]

作者单位： Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic. ^[1] Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.;Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. ^[2] 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. ^[3] Medical Department, Hematology, Charles University General Hospital, Prague, Czech Republic. ^[4] Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. ^[5] Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. ^[6] Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia. ^[7] Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic. ^[8] Department of Haematology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. ^[9] Faculty of Medicine, Center of Excellence CREATIC, Masaryk University, Brno, Czech Republic. ^[10]

关键词 acute myeloid leukaemia antifungal prophylaxis fungal infection venetoclax and azacitidine